XML 40 R27.htm IDEA: XBRL DOCUMENT v3.20.2
NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO THE STOCKHOLDERS OF ARGAN, INC. (Tables)
9 Months Ended
Oct. 31, 2020
NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO THE STOCKHOLDERS OF ARGAN, INC.  
Schedule of computations of basic and diluted net income (loss) per share

Basic and diluted net income (loss) per share amounts are computed as follows (shares in thousands except in notes (1) below the charts):

    

Three Months Ended October 31, 

    

2020

    

2019

Net income (loss) attributable to the stockholders of Argan, Inc.

$

9,454

$

(6,855)

Weighted average number of shares outstanding – basic

15,680

15,633

Effect of stock awards (1)

153

Weighted average number of shares outstanding – diluted

15,833

15,633

Net income (loss) per share attributable to the stockholders of Argan, Inc.

Basic

$

0.60

$

(0.44)

Diluted

$

0.60

$

(0.44)

(1)For the three months ended October 31, 2020, the weighted average number of shares determined on a dilutive basis excludes the effects of antidilutive stock options covering an aggregate of 506,501 shares of common stock. For the three months ended October 31, 2019, all common stock equivalents, which covered 1,243,000 shares of common stock, were considered to be antidilutive as the Company incurred a net loss for the period.

Nine Months Ended October 31, 

    

2020

    

2019

Net income (loss) attributable to the stockholders of Argan, Inc.

$

14,300

$

(35,501)

Weighted average number of shares outstanding – basic

15,659

15,617

Effect of stock awards (1)

136

Weighted average number of shares outstanding – diluted

15,795

15,617

Net income (loss) per share attributable to the stockholders of Argan, Inc.

Basic

$

0.91

$

(2.27)

Diluted

$

0.91

$

(2.27)

(1)   For the nine months ended October 31, 2020, the weighted average number of shares determined on a dilutive basis excludes the effects of antidilutive stock options covering an aggregate of 688,000 shares of common stock. For the nine months ended October 31, 2019, all common stock equivalents, which covered 1,243,000 shares of common stock, were considered to be antidilutive as the Company incurred a net loss for the period.